Semax: Complete Research Review of the Nootropic ACTH Analog Peptide
Shop Our Top Compounds
Semax Nootropic ACTH Analog Peptide: Complete Research Review
This article is for research purposes only. Semax is a research peptide and is not approved by the FDA for human therapeutic use. All products discussed are sold exclusively for laboratory and scientific research. Not for human consumption.
Introduction: A Synthetic Melanocortin Fragment with Broad Neurotrophic Activity
Semax (Met-Glu-His-Phe–Pro-Gly-Pro) is a synthetic analog of the adrenocorticotropic hormone fragment ACTH(4-10), belonging to a class of acth analogsβsynthetic peptides modeled after ACTH that exhibit neurotrophic, nootropic, and neuroprotective effects due to their structural similarity to fragments of the ACTH hormone. Semax has attracted significant attention in the neuroscience research community for its pronounced nootropic, neuroprotective, and neurotrophic properties. Originally developed at the Institute of Molecular Genetics of the Russian Academy of Sciences in the late 1980s, the Semax peptide represents a landmark achievement in rational peptide drug designβspecifically engineered to retain the neurotropic activity of the ACTH molecule while completely eliminating hormonal (steroidogenic) effects.
What distinguishes Semax from its parent ACTH fragment is the addition of a C-terminal Pro-Gly-Pro (PGP) tripeptide sequence, which dramatically enhances the moleculeβs resistance to enzymatic degradation and extends its biological half-life. The N-terminal region of the peptide is critical for its biological activity and stability, influencing its interactions and neurotrophic effects. This structural modification transforms a rapidly degraded endogenous peptide fragment into a stable research compound capable of exerting sustained effects on brain-derived neurotrophic factor (BDNF) expression, neurotransmitter signaling, immune modulation, and gene transcription.
Over three decades of investigation have yielded a substantial body of peer-reviewed literature documenting the effects of Semax across multiple experimental paradigmsβfrom cell culture systems and rodent models of cerebral ischemia to clinical observations in stroke patients. Most evidence regarding Semax comes from Russian studies, with limited large-scale clinical trials conducted in Western countries. It is important to note that Semax is not FDA approved in the United States, which impacts its clinical significance and raises concerns about quality, dosing, and sterility depending on sourcing and compounding practices. This comprehensive review examines the current state of Semax research, synthesizing findings on its chemical design, mechanisms of action, neurotrophic properties, cognitive effects, neuroprotective potential, and pharmacokinetic profile. For researchers exploring the peptide landscape, understanding Semax provides critical context for the broader field of melanocortin-derived nootropic compounds. Explore our full catalog of research peptides at IronPeak Peptides for your laboratory needs.
For a broader overview of research peptides and their mechanisms, visit our Peptide Glossary.
Chemical Structure and Rational Design of the Semax Peptide
The ACTH(4-10) Core Sequence
The foundation of the Semax peptide lies in the ACTH(4-10) fragment: Met-Glu-His-Phe. The N-terminal region of ACTH fragments, including this core sequence, plays a crucial role in the biological activity, stability, and interaction of these peptides with metal ions, which can influence their neurotrophic effects. Semax and related acth analogs are modeled after this core sequence to maximize neurotrophic, nootropic, and neuroprotective benefits while minimizing hormonal side effects. This tetrapeptide sequence was identified through decades of research on adrenocorticotropic hormone as the minimal fragment retaining the neurotrophic and cognitive-enhancing properties of the full 39-amino acid ACTH molecule, while being completely devoid of corticosteroid-stimulating hormonal activity. Early studies by Ashmarin, Myasoedov, and colleagues at the Institute of Molecular Genetics demonstrated that this fragment preserved the capacity to influence learning, memory, and attention in animal models (Ashmarin et al., 1997).
The Pro-Gly-Pro Stabilizing Modification
The critical innovation in Semax design was the attachment of the C-terminal tripeptide Pro-Gly-Pro (PGP), a hallmark of synthetic analog design for enhanced stability. Semax is a synthetic analog of ACTH(4-10), and the incorporation of this glyproline sequence was specifically intended to improve the peptideβs metabolic stability. Native ACTH fragments are rapidly degraded by aminopeptidases and other serum proteases, resulting in half-lives measured in minutes. The PGP modification confers resistance to peptidase-mediated cleavage, extending the effective biological activity of the molecule substantially. As described by Filippenkov et al. (2020), βPGP was included to ensure the resistance of Semax to peptidases,β a design principle that has proven remarkably successful.
Notably, the PGP fragment itself possesses independent biological activity. Research has demonstrated that Pro-Gly-Pro can activate the transcription of neurotrophin genes and their receptors following cerebral ischemia, suggesting that the full Semax molecule functions as a dual-action compoundβwith both the melanocortin core and the glyproline tail contributing to its overall pharmacological profile (Dmitrieva et al., 2010).
Molecular Properties
The Semax peptide has a molecular weight of approximately 813.97 Da and the amino acid sequence Met-Glu-His-Phe–Pro-Gly-Pro. The molecule is water-soluble and carries a net charge that varies with pH, with an isoelectric point influenced by the histidine and glutamic acid residues. Research has also demonstrated that Semax possesses a high affinity for copper(II) ions, forming stable complexes that may contribute to its protective properties against metal-induced cellular toxicity (TabbΓ¬ et al., 2015). The N-terminal region of Semax plays a key role in these metal ion interactions, enhancing the stability of the peptide-copper(II) complex.
Mechanism of Action: Multi-Target Neurotrophic Signaling
BDNF Upregulation and TrkB Receptor Activation
The most extensively characterized mechanism of Semax action involves the modulation of brain-derived neurotrophic factor (BDNF) and its high-affinity receptor TrkB, which is central to its nootropic action and impact on brain function. In a pivotal study, Dolotov et al. (2006) demonstrated that Semax binds specifically in the rat basal forebrain and increases BDNF protein levels upon intranasal application. The researchers reported that βSemax affects cognitive brain functions by modulating the expression and the activation of the hippocampal BDNF/trkB system.β This finding established a mechanistic link between Semax administration and the BDNF signaling cascadeβa pathway critically involved in synaptic plasticity, long-term potentiation, and neuronal survival.
The BDNF-stimulating effects of Semax are region-specific and temporally dynamic. Agapova et al. (2003) demonstrated that the Semax peptide stimulates BDNF expression across multiple brain regions in vivo, including the hippocampus, cortex, and basal forebrain. These regional effects align with the distribution of melanocortin receptors and suggest that the peptideβs nootropic properties and enhancement of brain function arise from widespread enhancement of neurotrophic signaling rather than localized receptor activation.
Melanocortin Receptor Interactions
As a structural analog of ACTH(4-10), Semax is positioned within the broader melanocortin system, which encompasses five receptor subtypes (MC1RβMC5R). A potential mechanism for Semax’s effects is its action as an antagonist or partial agonist at MC4 and MC5 receptors. Research has demonstrated that Semax does not activate MC4R in the same manner as Ξ±-melanocyte-stimulating hormone (Ξ±-MSH); rather, it was shown to antagonize the cAMP-inducing effect of Ξ±-MSH in HEK293 cells expressing MC4R (referenced in Filippenkov et al., 2020). This complex receptor pharmacologyβneither a simple agonist nor a classical antagonistβmay contribute to the unique spectrum of Semax bioactivities and distinguish it from other melanocortin peptides in research settings.
Neurotransmitter System Modulation
Research has revealed that Semax influences multiple neurotransmitter systems. Eremin et al. (2005) investigated the effects of Semax on dopaminergic and serotonergic neurochemical parameters in rodent brain regions. Their findings indicated that Semax modulates the turnover of both dopamine and serotonin in the striatum and hypothalamus, suggesting a broad-spectrum influence on monoaminergic neurotransmission. Furthermore, transcriptomic analyses have shown that Semax upregulates genes encoding dopamine receptors (Drd1, Drd2), GABA receptor subunits (Gabra5), and glutamate receptor components (Gria3, Grm3, Grm5) under ischemic conditions (Filippenkov et al., 2020).
Neurotrophic Factor Modulation: BDNF, NGF, and Beyond
Differential Regulation of Neurotrophin Gene Expression
One of the most compelling aspects of Semax research is its demonstrated ability to modulate the expression of multiple neurotrophin genes simultaneously. Eremin et al. (2007) examined the rapid changes in nerve growth factor (NGF) and BDNF gene expression following Semax administration. Their findings revealed a complex temporal pattern: neurotrophin gene expression was initially decreased in the hippocampus and retina at 20 minutes post-administration, followed by significant increases in the frontal cortex. This bidirectional, region-dependent modulation suggests that Semax orchestrates a coordinated neurotrophic response rather than simply elevating all growth factor levels uniformly. Notably, decreased BDNF levels have been associated with cognitive decline and increased biomarkers for Alzheimer’s disease, highlighting the potential relevance of Semax’s effects for neurodegenerative conditions.
Post-Ischemic Neurotrophin Activation
The neurotrophic effects of Semax are particularly pronounced under conditions of cerebral stress. Dmitrieva et al. (2010) demonstrated that both Semax and its PGP fragment activate the transcription of neurotrophins and their receptor genes following experimental cerebral ischemia. In their study, the researchers showed for the first time that Semax and PGP activate neurotrophin transcription in the cortex of rats subjected to ischemic injury, providing a potential molecular basis for the peptideβs observed neuroprotective effects. These data suggest that the Semax peptide may prime the brainβs endogenous neuroprotective machinery, enhancing the neurotrophic support system precisely when it is needed most. This neurotrophin activation is also potentially relevant for neurodegenerative disorders, where impaired neurotrophic signaling and neuroplasticity contribute to disease progression. The clinical significance of enhancing neurotrophic support in neurodegeneration lies in its potential to slow or modify disease outcomes, though further research is needed to fully establish these effects in clinical settings.
GDNF and Additional Growth Factor Pathways
Beyond BDNF and NGF, genomic profiling studies have revealed that Semax influences the expression of genes encoding vascular endothelial growth factor (VEGF) family members and their receptors in experimental focal ischemia models (Medvedeva et al., 2013). This multi-growth-factor modulation extends the potential significance of Semax research beyond purely neuronal applications into the realms of angiogenesis and vascular biology.
Cognitive Enhancement Research: Memory, Learning, and Attention
Passive Avoidance and Spatial Memory Paradigms
The nootropic properties of Semax have been documented across numerous behavioral paradigms, showing that Semax improves performance in cognitive tasks and influences mammalian behavior, including anxiety and depression. Research has demonstrated that Semax facilitates the acquisition of food-motivated and passive-avoidance tasks in healthy animals and exerts a protective effect in models of stress-induced memory impairment (Glazova et al., 2018; Levitskaya et al., 2008). In ischemic models specifically, Silachev et al. (2009) showed that Semax administration restored the ability of rats with ischemic lesions to the prefrontal cortex to form spatial memory in the Morris water mazeβa finding with significant implications for understanding how melanocortin analogs might support cognitive recovery following brain injury.
Protection Against Cognitive Impairment
Research by Inozemtsev et al. (2016) demonstrated that Semax prevents learning and memory inhibition caused by heavy metal exposure in rat models, and it is suggested that its cognitive-protective effects extend beyond ischemia-induced impairment to encompass toxicant-mediated cognitive decline. Additionally, Glazova et al. (2021) showed that Semax attenuated behavioral and neurochemical alterations following early-life SSRI (fluvoxamine) exposure, indicating neuroprotective potential against developmental neurotoxicity.
Mechanisms Underlying Cognitive Effects
The cognitive-enhancing properties of the Semax peptide are likely multifactorial, involving the convergence of BDNF/TrkB pathway activation, monoaminergic neurotransmitter modulation, and gene expression changes affecting synaptic plasticity-related genes. Transcriptomic data from Filippenkov et al. (2020) showed that Semax upregulates genes associated with synaptic function (including complexin-2, neurod6, and multiple receptor genes), providing molecular evidence for its nootropic actions at the gene expression level.
Neuroprotection Research: Stroke, Ischemia, and Oxidative Stress
Experimental Stroke Models
Neuroprotection represents the most clinically advanced area of Semax research, particularly in models of central nervous system injury. The peptide has been extensively studied in both permanent and transient middle cerebral artery occlusion (MCAO) models. Bashkatova et al. (2001) demonstrated that Semax prevents the enhanced nitric oxide generation in the cerebral cortex of rats with incomplete global ischemiaβa key finding given the role of excess nitric oxide in ischemic neuronal death. Storozhevykh et al. (2007) showed that Semax promotes the survival of neurons during glutamate toxicity by stabilizing calcium homeostasis, addressing another critical mechanism of ischemic cell death. Similar peptide-based interventions are also being explored for myocardial infarction and other cardiovascular conditions, highlighting the broader therapeutic potential of ACTH analog peptides.
Genome-Wide Transcriptional Response to Ischemia
The landmark genome-wide study by Medvedeva et al. (2014) used Expression BeadChip microarrays to analyze the complete transcriptional response to Semax in ischemized rat brain cortex. Their analysis revealed that Semax predominantly enhanced the expression of genes related to the immune system, with over 50% of Semax-responsive genes at 24 hours post-ischemia belonging to immune-response categories. Genes encoding immunoglobulins and chemokines formed the most prominent upregulated groups, suggesting that immunomodulation is a key mechanism of Semax neuroprotection.
Building on this work, Filippenkov et al. (2020) employed RNA-Seq analysis to study Semax effects in a transient MCAO model with reperfusion. They identified 394 differentially expressed genes and made a critical discovery: βSemax suppressed the expression of genes related to inflammatory processes and activated the expression of genes related to neurotransmission. In contrast, ischaemiaβreperfusion alone activated the expression of inflammation-related genes and suppressed the expression of neurotransmission-related genes.β This compensatory patternβin which Semax essentially reverses the ischemia-induced transcriptional programβrepresents one of the most compelling mechanistic explanations for its neuroprotective effects.
Clinical Observations in Ischemic Stroke
Semax has been evaluated in clinical settings for ischemic stroke. Gusev et al. (1997) reported on the effectiveness of Semax in the acute period of hemispheric ischemic stroke in a clinical and electrophysiological study. More recently, Gusev et al. (2018) demonstrated that early rehabilitation combined with Semax administration increased BDNF plasma levels, accelerated functional recovery, and improved motor performance in stroke patients at different stages of recovery. Miasoedova et al. (1999) investigated the immunobiochemical mechanisms of Semaxβs neuroprotective properties during the acute period of ischemic stroke, providing early clinical evidence for the peptideβs immune-modulating actions. The clinical significance of these findings suggests that Semax may offer meaningful improvements in stroke recovery outcomes, though further research is needed to fully establish its impact in diverse patient populations.
Anxiolytic and Antidepressant Properties: Serotonergic and Dopaminergic Interactions
Behavioral Evidence for Anxiolytic Effects
Research has demonstrated that chronic Semax administration produces measurable anxiolytic and antidepressant-like effects in rodent behavioral models, indicating its influence on mammalian behavior and potential contribution to mood regulation. Vilensky et al. (2007) showed that chronic Semax administration at 1β2 weeks induced anxiolytic and antidepressant effects in white rats without influencing exploratory activityβa profile suggesting selective modulation of anxiety-related circuits rather than generalized sedation or behavioral suppression.
Serotonergic and Dopaminergic Modulation
The anxiolytic properties of Semax are likely mediated through its effects on monoaminergic neurotransmitter systems. Eremin et al. (2005) documented that Semax modulates serotonergic system activity in the striatum, with chronic administration altering serotonin and dopamine turnover in the hypothalamus. The transcriptomic data from RNA-Seq analyses further support this mechanism, showing that Semax upregulates genes involved in dopaminergic, serotonergic, and GABAergic synaptic transmission under ischemic conditions.
Relevance to Stress-Response Research
The combination of nootropic, anxiolytic, and neuroprotective properties positions Semax as a particularly interesting compound for stress-response research. The peptide’s ability to attenuate stress-induced memory impairment (Glazova et al., 2018) and its antidepressant-like behavioral profile suggest involvement of the hypothalamic-pituitary-adrenal (HPA) axisβthe very system from which its parent molecule ACTH derives. Researchers interested in exploring nootropic peptides can find high-purity Semax and related compounds at IronPeak Peptides.
Immune System Modulation: Cytokine Regulation and Anti-Inflammatory Pathways
Genome-Wide Immune Gene Regulation
One of the most significant discoveries in Semax research was the extent of its immunomodulatory activity. The genome-wide analysis by Medvedeva et al. (2014) revealed that immune response genes represented over 50% of all genes showing Semax-induced altered expression at 24 hours after permanent MCAO. The peptide enhanced the expression of genes encoding immunoglobulins (with fold changes up to 15-fold for some immunoglobulin heavy chain variants), chemokines (CXCL9, CXCL10, CXCL13, CCL5, CCL7, CCL19), and MHC class I and II molecules.
Anti-Inflammatory Compensation Under Ischemic Conditions
Filippenkov et al. (2020) demonstrated that the compensatory effect of Semax involves suppression of pro-inflammatory signaling pathwaysβincluding phagosome, IL-17 signaling, TNF signaling, and p53 signalingβthat are pathologically activated during ischemia-reperfusion. Simultaneously, Semax activated neurotransmitter-related pathways (dopaminergic, glutamatergic, cholinergic, and calcium signaling). This dual actionβanti-inflammatory suppression combined with neurotransmitter restorationβprovides a comprehensive framework for understanding how the peptide mitigates ischemic brain damage.
Cytokine Balance Under Social Stress
Research has extended the immunomodulatory characterization of Semax to stress-induced immune dysregulation. Studies using βsocial stressβ models have demonstrated that Semax functions as an effective immune corrector, restoring cellular and humoral immunogenesis reactions and phagocytic activity of neutrophils (Gorbunov et al., 2019). These findings suggest that the immune-modulatory properties of Semax are not limited to ischemic contexts but represent a broader regulatory capacity.
Gene Expression Studies: Transcriptomic Profiling and Molecular Signatures
Microarray Analyses in Permanent Ischemia
The application of genome-wide expression profiling technologies has transformed Semax research from a pharmacological description to a molecular-level understanding. A genome-wide analysis published in BMC Genomics utilized Illumina RatRef-12 Expression BeadChips (covering 22,226 genes), where Medvedeva et al. (2014) identified 96 genes with altered expression at 3 hours and 68 genes at 24 hours post-ischemia under Semax treatment. Notably, different gene groups responded at the two time points, with only 10 genes overlappingβand those showing contradictory (opposite-direction) changes between the early and late time points.
RNA-Seq Analysis in Transient Ischemia-Reperfusion
The most comprehensive transcriptomic study of Semax action employed RNA-Seq technology in a transient MCAO model. Filippenkov et al. (2020) identified 394 differentially expressed genes (191 upregulated, 203 downregulated) in the subcortical structures of rat brain at 24 hours after tMCAO under Semax treatment. Hierarchical cluster analysis demonstrated a striking pattern: Semax increased expression levels of genes reduced by ischemia and decreased expression levels of genes elevated by ischemiaβa nearly perfect compensatory response at the transcriptomic level. This work was deposited in the Sequence Read Archive (SRP148632, PRJNA491404), making it available for independent reanalysis.
Functional Pathway Analysis
KEGG pathway analysis revealed 25 signaling pathways associated with Semax-induced differentially expressed genes. Of these, 17 overlapped with pathways disrupted by ischemia-reperfusion. Eight pathways activated by ischemia (phagosome, PI3K-Akt, MAPK signaling) were suppressed by Semax, while eight pathways suppressed by ischemia (amphetamine addiction, retrograde endocannabinoid signaling, glutamatergic and dopaminergic synapses) were activated by Semax. This bidirectional pathway compensation represents the most detailed molecular description of Semax neuroprotection to date.
Pharmacokinetics: Intranasal Delivery, BBB Penetration, and Metabolic Stability
Intranasal Bioavailability and Brain Penetration
The pharmacokinetics of Semax have been studied using radiolabeled peptide tracking. Shevchenko et al. (2006) used tritium-labeled Semax to study the kinetics of penetration into the brain and blood of rats following intranasal administration (50 ΞΌg/kg). Their study demonstrated that intranasally administered Semax reaches the brain rapidly, with detectable levels in brain tissue within minutes of administration. Intranasal delivery is the primary route of administration studied in research settings, as it may partially bypass the blood-brain barrier (BBB) through the olfactory and trigeminal nerve pathways. Compared to intraperitoneal injection, intranasal Semax has shown a more pronounced improvement in learning and cognitive enhancement in animal studies.
Serum Half-Life and Peptidase Resistance
The Pro-Gly-Pro modification gives Semax significantly enhanced metabolic stability compared to native ACTH(4-10). Published estimates indicate that the half-life of Semax in serum exceeds one hour (Kolomin et al., 2013)βa substantial improvement over the unmodified ACTH fragment, which is degraded within minutes. After intravenous administration, approximately 0.01% of Semax penetrates the blood-brain barrier, while intranasal delivery achieves considerably higher brain concentrations due to direct nose-to-brain transport pathways.
Dose-Response Relationships in Research
In published research protocols, Semax has been administered at varying doses depending on the model system. In neuroprotection studies, researchers have typically administered 100 ΞΌg/kg via intraperitoneal injection (Medvedeva et al., 2014) or 10 ΞΌg/100g body weight (Filippenkov et al., 2020) in rat models, with intraperitoneal injection being a common route in animal studies. In clinical investigations, intranasal formulations at 1% concentration have been employed (Gusev et al., 1997; 2018). These dosing parameters reflect the research context and are cited solely for methodological reference.
Comparison with Selank and Other Nootropic Peptides
Semax vs. Selank: Complementary Melanocortin Analogs
Semax and Selank represent two complementary branches of Russian regulatory peptide pharmacology. Both are synthetic heptapeptides classified as acth analogsβpeptides modeled after fragments of the ACTH hormoneβdeveloped at the Institute of Molecular Genetics. While sharing structural similarities as acth analogs, they exhibit distinct neurotrophic and nootropic profiles:
Parent molecule: Semax derives from ACTH(4-10), while Selank is based on the endogenous tetrapeptide tuftsin (Thr-Lys-Pro-Arg) with the same PGP stabilizing modification.
Primary research focus: Semax research emphasizes cognitive enhancement and neuroprotection, while Selank is primarily investigated for anxiolytic effects and stress resilience.
Neurotransmitter targets: Semax predominantly influences dopaminergic and serotonergic systems with pronounced BDNF modulation, while Selank primarily modulates GABAergic and serotonergic transmission with effects on enkephalin metabolism.
BDNF effects: Both peptides increase BDNF expression, though Semax demonstrates more robust and well-characterized neurotrophic factor modulation across multiple brain regions.
Immune modulation: Both peptides show immunomodulatory activity, but Semax demonstrates more extensive effects on immunoglobulin and chemokine gene expression in ischemic models.
Semax in the Context of Broader Nootropic Peptide Research
Compared to other nootropic peptides in the research landscapeβincluding BPC-157, Dihexa, and N-Acetyl Selankβthe Semax peptide occupies a unique position as a melanocortin-derived compound with both cognitive-enhancing and neuroprotective properties supported by clinical-level observations. The nootropic action of Semax is notable for its influence on neurotrophic factors, neurotransmitter systems such as dopamine and serotonin, and its ability to enhance neuroplasticity, learning, and memory. Its dual mechanism of neurotransmitter restoration and inflammatory suppression distinguishes it from peptides that act primarily through single-target receptor activation.
Frequently Asked Questions About Semax Peptide Research
What is Semax and what is its chemical structure?
Semax (Met-Glu-His-Phe–Pro-Gly-Pro) is a synthetic heptapeptide analog of the ACTH(4-10) fragment with a C-terminal Pro-Gly-Pro (PGP) tripeptide modification for enhanced metabolic stability. It has a molecular weight of approximately 813.97 Da and was originally developed at the Institute of Molecular Genetics of the Russian Academy of Sciences. The PGP modification confers resistance to peptidase degradation without introducing D-amino acids or hydrophobic radicals, making it a rationally designed research peptide.
How does Semax affect BDNF expression in research models?
Research has demonstrated that Semax increases brain-derived neurotrophic factor (BDNF) protein levels in multiple brain regions, including the basal forebrain, hippocampus, and cortex. Dolotov et al. (2006) showed that Semax binds specifically in basal forebrain tissue and modulates the BDNF/TrkB signaling system. The neurotrophic effects are temporally dynamic, with differential regulation patterns observed across brain regions at different time points following administration.
What neuroprotective effects has Semax demonstrated in ischemia research?
In experimental stroke models, Semax has demonstrated multiple neuroprotective mechanisms including: prevention of excess nitric oxide generation (Bashkatova et al., 2001), stabilization of neuronal calcium homeostasis during glutamate toxicity (Storozhevykh et al., 2007), suppression of inflammatory gene expression, and restoration of neurotransmitter-related gene expression patterns disrupted by ischemia-reperfusion (Filippenkov et al., 2020). Clinical observations have noted improved functional recovery and increased plasma BDNF levels in stroke patients (Gusev et al., 2018).
How does Semax compare to Selank in research applications?
While both are synthetic heptapeptides with PGP stabilizing modifications, Semax derives from ACTH(4-10) and is primarily investigated for cognitive enhancement and neuroprotection, whereas Selank derives from tuftsin and focuses on anxiolytic and stress-resilience research. Semax shows more pronounced BDNF modulation and broader neurotransmitter system effects, while Selank demonstrates stronger GABAergic modulation and enkephalin pathway involvement.
What is the pharmacokinetic profile of Semax following intranasal administration?
Studies using radiolabeled Semax have demonstrated rapid brain penetration following intranasal administration in rat models (Shevchenko et al., 2006). The Pro-Gly-Pro modification extends serum half-life to over one hour, a substantial improvement over native ACTH(4-10). Intranasal delivery achieves higher brain concentrations than intravenous administration, likely through direct nose-to-brain transport pathways bypassing the blood-brain barrier.
What gene expression changes does Semax induce under ischemic conditions?
Genome-wide transcriptomic analyses have identified hundreds of differentially expressed genes following Semax administration in ischemia models. Filippenkov et al. (2020) identified 394 DEGs in a transient MCAO model, demonstrating that Semax compensates for ischemia-induced transcriptional disruption by upregulating neurotransmitter-related genes (dopamine receptors, GABA receptors, glutamate receptors) and downregulating inflammatory genes (chemokines, acute-phase proteins, innate immunity components).
Conclusion: Semax as a Multi-Target Neuropeptide Research Compound
Semax is a synthetic peptide belonging to the class of ACTH analogsβengineered fragments modeled after the adrenocorticotropic hormone (ACTH) that exhibit neurotrophic, nootropic, and neuroprotective effects. As one of the most thoroughly characterized nootropic peptides, Semaxβs clinical significance lies in its demonstrated ability to modulate brain functions such as learning, memory, and behavior, with research suggesting potential therapeutic benefits in neurodegenerative and mental health conditions. While preclinical and clinical studies highlight promising mechanisms, the actual clinical significance of these findings depends on the specific context and condition, underscoring the need for careful interpretation of research data.
The transcriptomic studies by Medvedeva et al. (2014) and Filippenkov et al. (2020) have been particularly transformative, revealing that Semaxβs neuroprotective mechanism involves a near-complete reversal of the pathological gene expression program induced by ischemia-reperfusion. This compensatory actionβsuppressing inflammation while restoring neurotransmissionβprovides a molecular framework for understanding the peptideβs broad therapeutic potential observed in preclinical and clinical research settings.
For research laboratories investigating neurotrophic peptides, melanocortin analogs, or neuroprotective strategies, Semax represents a compound with an unusually rich evidence base. Its well-characterized pharmacology, defined structure-activity relationships, and extensive gene expression data make it an invaluable tool for advancing our understanding of peptide-mediated neuroprotection and cognitive enhancement.
Explore IronPeak Peptidesβ complete catalog of research-grade peptides including Semax and related compounds for your laboratory investigations. For a comprehensive understanding of peptide research terminology, visit our Peptide Glossary.
Research Disclaimer
The information presented in this article is derived from published scientific literature and is provided exclusively for educational and research purposes. Semax is sold as a research chemical for in vitro and animal research only. It is not intended for human consumption and is not approved by the FDA for the diagnosis, treatment, cure, or prevention of any disease. The studies cited reflect findings from controlled research environments and should not be interpreted as medical advice or therapeutic recommendations. Researchers should consult all applicable institutional guidelines and regulatory requirements before conducting experiments with this compound.
References
Ashmarin IP, Nezavibatko VN, Myasoedov NF, et al. βA nootropic adrenocorticotropin analog 4-10-semax (15 years experience in its design and study).β Zh Vyssh Nerv Deiat Im I P Pavlova, 47(2), 420β430, 1997. PMID: 9173745
Dolotov OV, Karpenko EA, Inozemtseva LS, et al. βSemax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus.β Brain Research, 1117(1), 54β60, 2006. DOI: 10.1016/j.brainres.2006.07.108
Agapova TY, Agniullin YV, Silachev DN, et al. βThe heptapeptide SEMAX stimulates BDNF expression in different areas of the rat brain in vivo.β Doklady Biological Sciences, 391, 337β339, 2003. PMID: 14556513
Filippenkov IB, Stavchansky VV, Denisova AE, et al. βNovel Insights into the Protective Properties of ACTH(4-7)PGP (Semax) Peptide at the Transcriptome Level Following Cerebral IschaemiaβReperfusion in Rats.β Genes, 11(6), 681, 2020. DOI: 10.3390/genes11060681
Medvedeva EV, Dmitrieva VG, Povarova OV, et al. βThe peptide semax affects the expression of genes related to the immune and vascular systems in rat brain focal ischemia: genome-wide transcriptional analysis.β BMC Genomics, 15, 228, 2014. DOI: 10.1186/1471-2164-15-228
Gusev EI, Skvortsova VI, Miasoedov NF, et al. βEffectiveness of semax in acute period of hemispheric ischemic stroke (a clinical and electrophysiological study).β Zh Nevrol Psikhiatr Im S S Korsakova, 97, 26β34, 1997. PMID: 11517472
Gusev EI, Martynov MY, Kostenko EV, et al. βThe efficacy of semax in the treatment of patients at different stages of ischemic stroke.β Zh Nevrol Psikhiatr Im S S Korsakova, 118(3), 61β68, 2018. DOI: 10.17116/jnevro20181183261-68
Eremin KO, Kudrin VS, Saransaari P, et al. βSemax, An ACTH(4-10) Analogue with Nootropic Properties, Activates Dopaminergic and Serotoninergic Brain Systems in Rodents.β Neurochemical Research, 30(12), 1493β1500, 2005. DOI: 10.1007/s11064-005-8826-8
Bashkatova VG, Koshelev VB, Fadyukova OE, et al. βNovel synthetic analogue of ACTH 4-10 (Semax) but not glycine prevents the enhanced nitric oxide generation in cerebral cortex of rats with incomplete global ischemia.β Brain Research, 894(1), 145β149, 2001. DOI: 10.1016/S0006-8993(00)03324-2
Storozhevykh TP, Tukhbatova GR, Senilova YE, et al. βEffects of semax and its Pro-Gly-Pro fragment on calcium homeostasis of neurons and their survival under conditions of glutamate toxicity.β Bulletin of Experimental Biology and Medicine, 143(5), 601β604, 2007. DOI: 10.1007/s10517-007-0192-x
Dmitrieva VG, Povarova OV, Skvortsova VI, et al. βSemax and Pro-Gly-Pro activate the transcription of neurotrophins and their receptor genes after cerebral ischemia.β Cellular and Molecular Neurobiology, 30(1), 71β79, 2010. DOI: 10.1007/s10571-009-9432-0
Eremin KO, Kudrin VS, Grivennikov IA, et al. βNeurotrophin gene expression in rat brain under the action of Semax.β Doklady Biochemistry and Biophysics, 412, 25β29, 2007. PMID: 17353092
Vilensky DA, Levitskaya NG, Andreeva LA, et al. βEffects of Chronic Semax Administration on Exploratory Activity, Anxiety, and Depression in White Rats.β Bulletin of Experimental Biology and Medicine, 144(2), 214β217, 2007. PMID: 17850024
Kolomin TA, Shadrina MI, Slominsky PA, et al. βA New Generation of Drugs: Synthetic Peptides Based on Natural Regulatory Peptides.β Neuroscience & Medicine, 4, 223β252, 2013. DOI: 10.4236/nm.2013.44035
TabbΓ¬ G, MagrΓ¬ A, Giuffrida A, et al. βSemax, an ACTH4-10 peptide analog with high affinity for copper(II) ion and protective ability against metal induced cell toxicity.β Journal of Inorganic Biochemistry, 142, 39β46, 2015. DOI: 10.1016/j.jinorgbio.2014.09.008
Miasoedova NF, Skvortsova VI, Nasonov EL, et al. βInvestigation of mechanisms of neuro-protective effect of semax in acute period of ischemic stroke.β Zh Nevrol Psikhiatr Im S S Korsakova, 99, 15β19, 1999. PMID: 10358912
Shevchenko KV, Nagaev IY, Alfeeva LY, et al. βKinetics of Semax penetration into the brain and blood of rats after its intranasal administration.β Russian Journal of Bioorganic Chemistry, 32(1), 57β62, 2006. DOI: 10.1134/S1068162006010079
Glazova NY, Manchenko DM, Volodina MA, et al. βSemax, synthetic ACTH(4-10) analogue, attenuates behavioural and neurochemical alterations following early-life fluvoxamine exposure in white rats.β Neuropeptides, 86, 102114, 2021. DOI: 10.1016/j.npep.2020.102114
Related Research
🔬 Explore Research Peptides
- Thymosin Alpha-1 10mg — $65.00
- IPP-1 ELO — $70.00
- Recovery Research Stack — $135.00
- AOD-9604 5mg — $44.99
